Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291 | Chief Financial Officer | May 15, 2025 | May 28, 2025 |
| Sorrento Therapeutics, Inc.SRNE · Entity 109201 | Executive VP and CFO | February 03, 2017 | February 03, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MARAVAI LIFESCIENCES HOLDINGS, INC.
Report date May 15, 2025 · Filed May 28, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 674,636 |
Reported balance
After 2025-05-15 transaction · row 1
1 source rowRow 1 · 2025-05-15 · Grant · Acquired 876 · Balance 674,636 F1: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 876 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 876 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.
Sorrento Therapeutics, Inc.
Report date February 03, 2017 · Filed February 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,000 |
Reported balance
After 2017-02-03 transaction · row 1
1 source rowRow 1 · 2017-02-03 · Purchase · Acquired 3,000 · Balance 7,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 28, 2025 17:52 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 876 | $1.67 | $1,462.92 |
DisclosureSEC source: 0001823239-25-000069 · wk-form4_1748469145.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 674,636 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 876 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 17:58 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 394,478 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-25-000056 · wk-form4_1742421504.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 673,760 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of March 15, 2026, March 15, 2027, and March 15, 2028, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 17:27 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 8,648 | $2.64 | $22,830.72 |
DisclosureSEC source: 0001823239-25-000044 · wk-form4_1742419628.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,282 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 16:44 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 2,326 | $4.10 | $9,536.60 |
DisclosureSEC source: 0001823239-25-000022 · wk-form4_1740001486.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,930 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 16:19 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 46,344 | $4.56 | $211,328.64 |
DisclosureSEC source: 0001823239-25-000015 · wk-form4_1737148752.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,256 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| October 31, 2024 Filed Nov 12, 2024 17:18 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 1,906 | $5.70 | $10,864.20 |
DisclosureSEC source: 0001823239-24-000117 · wk-form4_1731449889.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,600 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 1,906 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| April 30, 2024 Filed May 2, 2024 18:46 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 1,780 | $5.70 | $10,146.00 |
DisclosureSEC source: 0001823239-24-000055 · wk-form4_1714689986.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,694 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 1,780 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 17:55 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 8,624 | $7.70 | $66,404.80 |
DisclosureSEC source: 0001823239-24-000036 · wk-form4_1710798913.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,914 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 18:47 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 2,664 | $5.48 | $14,598.72 |
DisclosureSEC source: 0001823239-24-000025 · wk-form4_1708472810.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,538 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 18:26 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 250,277 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-24-000010 · wk-form4_1705620365.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,202 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in one-half (1/2) increments on each of January 15, 2025, and January 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 31, 2023 Filed Nov 16, 2023 17:22 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 1,861 | $5.83 | $10,849.63 |
DisclosureSEC source: 0001823239-23-000096 · wk-form4_1700173315.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,925 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 1,861 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| April 28, 2023 Filed Jul 19, 2023 16:51 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 874 | $11.72 | $10,243.28 |
DisclosureSEC source: 0001823239-23-000068 · wf-form4_168979989281869.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,064 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 874 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:52 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantEmployee Stock Options (Right to Buy) · Derivative | 143,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001823239-23-000028 · wf-form4_167908631546730.xml · derivative · entry 2 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 Underlying: Class A Common Stock · 143,000 shares Expires 2033-03-15 F2 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on April 15, 2023 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:52 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 72,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-23-000028 · wf-form4_167908631546730.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,190 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of March 15, 2024, March 15, 2025, and March 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:32 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 2,611 | $15.23 | $39,765.53 |
DisclosureSEC source: 0001823239-23-000007 · wf-form4_167666953300244.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,683 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| October 31, 2022 Filed Nov 9, 2022 17:35 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 478 | $14.11 | $6,744.58 |
DisclosureSEC source: 0001823239-22-000063 · wf-form4_166803332873857.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,294 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 478 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| April 29, 2022 Filed Jun 27, 2022 19:55 UTC Amendment | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 427 | $22.95 | $9,799.65 |
DisclosureSEC source: 0001823239-22-000032 · wf-form4a_165637410200444.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,816 F1 · kind: Amended to note that this is a voluntary filing. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 427 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| April 29, 2022 Filed Jun 27, 2022 18:42 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 427 | $22.95 | $9,799.65 |
DisclosureSEC source: 0001823239-22-000026 · wf-form4_165636973465957.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,816 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 427 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:00 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantEmployee Stock Option (Right to Buy) · Derivative | 36,200 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0000899243-22-003418 · doc4.xml · derivative · entry 4 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,200 Underlying: Class A Common Stock · 36,200 shares Expires 2032-01-25 F3 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on March 15, 2022 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:00 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 19,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-003418 · doc4.xml · nonDerivative · entry 3 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,389 F2 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| October 31, 2021 Filed Jan 27, 2022 16:00 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 392 | $22.95 | $8,996.40 |
DisclosureSEC source: 0000899243-22-003418 · doc4.xml · nonDerivative · entry 2 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889 F1 · timeliness: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 889 shares of Class A Common Stock was also exempt pursuant to Rule 16b-3(c). Read SEC document |
| April 30, 2021 Filed Jan 27, 2022 16:00 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 497 | $22.95 | $11,406.15 |
DisclosureSEC source: 0000899243-22-003418 · doc4.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497 F1 · timeliness: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 889 shares of Class A Common Stock was also exempt pursuant to Rule 16b-3(c). Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 17:32 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantEmployee Stock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031947 · doc4.xml · derivative · entry 1 Herde Kevin · CIK 0001671595 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Class A Common Stock · 60,000 shares Expires 2030-11-19 F1 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan in connection with the pricing of the Issuer's initial public offering. These options will vest 25% on November 19, 2021 and in equal monthly installments thereafter over the next three years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 03, 2017 Filed Feb 3, 2017 19:48 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | PurchaseCommon Stock | 3,000 | $5.15 | $15,450.00 |
DisclosureSEC source: 0000899243-17-002785 · doc4.xml · nonDerivative · entry 1 Herde Kevin · CIK 0001671595 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.